Telomir Pharmaceuticals, Inc. has regained compliance with Nasdaq listing requirements following its 2025 Annual Meeting of Shareholders, resolving a prior deficiency.
Key takeaways
The company received a Nasdaq letter on March 30, 2026 confirming compliance with Listing Rule 5620(a).
Compliance was achieved through holding the 2025 Annual Meeting of Shareholders.
Nasdaq has determined the matter closed, eliminating the risk of delisting.
The notification resolves a previously disclosed listing deficiency.